Literature DB >> 7550987

Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma.

B A Staton1, M G Johnson, J M Friis, W J Adams.   

Abstract

A method for the determination of a bisheteroarylpiperazine, non-nucleoside HIV-1 reverse transcriptase inhibitor, delavirdine, and its N-desisopropyl metabolite in human plasma, is described. Samples were deproteinized by addition of two parts of a solution of internal standard in acetonitrile (1 microgram/ml) to one part plasma. The supernatant was diluted with 10 mM phosphate buffer, pH 6.0, and injected onto the HPLC system. Fluorescence of the eluent was monitored with excitation at 302 nm and emission at 425 nm. Quantitation of delavirdine and its metabolite was achieved by comparing the peak-height ratio of each component relative to the internal standard to a through-the-origin linear regression curve determined from fortified plasma calibration standards. The assay was linear over the concentration range 0.02-17 microM for both delavirdine and its metabolite. The precision of the method, as expressed by the mean C.V. of the back-calculated, non-zero, standard concentrations, was +/- 4.4% for delavirdine and +/- 4.3% for the metabolite. The assay has been validated and utilized to analyze samples from human and animal pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550987     DOI: 10.1016/0378-4347(95)00045-k

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  6 in total

Review 1.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.

Authors:  M T Borin; S R Cox; B D Herman; B J Carel; R D Anderson; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Authors:  P F Smith; R DiCenzo; G D Morse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.

Authors:  M F Para; P Meehan; J Holden-Wiltse; M Fischl; G Morse; R Shafer; L M Demeter; K Wood; T Nevin; N Virani-Ketter; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection.

Authors:  Gene D Morse; Margaret A Fischl; Mark J Shelton; Steve R Cox; Leslie Thompson; Andrew A Della-Coletta; William W Freimuth
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

6.  Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.

Authors:  Gene D Morse; Susan E Cohn; Mark J Shelton; Carol Greisberger; Steven R Cox; Andrew A Della-Coletta; William W Freimuth; Richard C Reichman
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.